Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
| ▸ | GABRP | O00591 | 3/20 | 0.49 |
| ▸ | GABRD | O14764 | 3/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.49 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.49 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.49 |
| ▸ | GABRE | P78334 | 3/20 | 0.49 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.49 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.49 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.49 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | F7 | P08709 | 1/20 | 0.48 |
| ▸ | F3 | P13726 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3366419 | 0.80 | KMT2A (0.59) | CA9GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL6648102 | 0.77 | NPC1 (0.62) | CA9CA12MEN1KMT2AMAPT | |
| SCHEMBL2340821 | 0.75 | MAPT (0.81) | CA9GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL7682710 | 0.74 | F7 (0.55) | CA9GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL9238146 | 0.73 | GABRP (0.57) | CA9GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL12113006 | 0.73 | MAPT (0.71) | CA9GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL6718661 | 0.71 | AR (0.55) | CA9GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL7233114 | 0.71 | MEN1 (0.43) | CA9GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL9189119 | 0.71 | KDM1A (0.61) | CA9GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL6524056 | 0.71 | MAPT (0.69) | CA9GABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186132-A1 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2004-09-23 | — | — | US | disclosed |
| EP-1043325-B1 | Steroid receptor modulator compounds and methods | LIGAND PHARM INC (US) | 2004-06-16 | — | — | EP | disclosed |
| US-6696459-B1 | USING HIGH AFFINITY, HIGH SELECTIVITY QUINOLINE DERIVATIVESW | LIGAND PHARMACEUTICALS INC. | 2004-02-24 | — | — | US | disclosed |
| EP-1382597-A2 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. (US) | 2004-01-21 | — | — | EP | disclosed |
| US-6448405-B1 | COUPLING A 2-HALO-5-NITROBENZOIC ACID AND A 2-METHOXYPHENYL BORONIC ACID; CYCLIZING TO A NITROBENZOCOUMARIN; REDUCING TO THE AMINE; CONVERTING TO A COUMARINO(3,4-F)QUINOLINE; REDUCTION TO A 5H-CHROMENO(3,4-F)QUINOLINE | LIGAND PHARMACEUTICALS INCORPORATED | 2002-09-10 | — | — | US | disclosed |
| EP-1043325-A1 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-10-11 | — | — | EP | disclosed |
| EP-1043326-A1 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-10-11 | — | — | EP | disclosed |
| EP-1043315-A1 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-10-11 | — | — | EP | disclosed |
| EP-1041071-A1 | Methods for the preparation of coumarine derivatives | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-10-04 | — | — | EP | disclosed |
| EP-1041066-A1 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-10-04 | — | — | EP | disclosed |
| US-5994544-A | PRODUCING A 5H-CHROMENO(3,4-F)QUINOLINE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-11-30 | — | — | US | disclosed |
| US-5696127-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5696133-A | ADMINISTERING COMPOUND WHICH MODULATES ACTIVITY OF PROGESTERONE RECEPTOR | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5696130-A | Tricyclic steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5693646-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5693647-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5688808-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| US-5688810-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0800519-A1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996019458-A2 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186132-A1 | Steroid receptor modulator compounds and methods | NR5A1, ESRRA, NR3C2 | CA9 4070/4885GABRP 256/4885GABRD 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.